{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:21Z","timestamp":1792839741481,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025190","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-CN-342-5420"],"award-info":[{"award-number":["IN-CN-342-5420"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jve.2024.100571","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:57:14Z","timestamp":1733187434000},"page":"100571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-life study on the effectiveness and safety of sofosbuvir\/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-9283","authenticated-orcid":false,"given":"Jiayi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jve.2024.100571_bib1","doi-asserted-by":"crossref","first-page":"1041201","DOI":"10.3389\/fpubh.2023.1041201","article-title":"The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019","volume":"11","author":"Yang","year":"2023","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.jve.2024.100571_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jve.2024.100571_bib3","article-title":"Secular trends of acute viral hepatitis incidence and mortality in China, 1990 to 2019 and its prediction to 2030: the global burden of disease study 2019","volume":"9","author":"Su","year":"2022","journal-title":"Front Med (Lausanne)."},{"issue":"6","key":"10.1016\/j.jve.2024.100571_bib4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/ijms20061358","article-title":"Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review","volume":"20","author":"Kanda","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jve.2024.100571_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/JHC.S347959","article-title":"Perspectives on the underlying etiology of HCC and its effects on treatment outcomes","volume":"10","author":"Ito","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"issue":"S1","key":"10.1016\/j.jve.2024.100571_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/liv.13659","article-title":"The impact of treatment of hepatitis C with DAAs on the occurrence of HCC","volume":"38","author":"Roche","year":"2018","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jve.2024.100571_bib7","doi-asserted-by":"crossref","DOI":"10.2217\/hep-2020-0010","article-title":"HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance","volume":"7","author":"Pascut","year":"2020","journal-title":"Hepatic Oncol"},{"issue":"5","key":"10.1016\/j.jve.2024.100571_bib8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jve.2024.100571_bib9","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterol"},{"issue":"2","key":"10.1016\/j.jve.2024.100571_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatol"},{"issue":"2","key":"10.1016\/j.jve.2024.100571_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir\u2013velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.jve.2024.100571_bib12","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-016-0648-2","article-title":"Sofosbuvir\/velpatasvir: a review in chronic hepatitis C","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"issue":"42","key":"10.1016\/j.jve.2024.100571_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031183","article-title":"Safety and efficacy of sofosbuvir-velpatasvir: a meta-analysis","volume":"101","author":"Ren","year":"2022","journal-title":"Medicine (Baltim)"},{"issue":"11","key":"10.1016\/j.jve.2024.100571_bib14","first-page":"1046","article-title":"[Twelve-week of sofosbuvir\/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study]","volume":"29","author":"Xu","year":"2021","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.jve.2024.100571_bib15","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2147\/IDR.S312902","article-title":"Sofosbuvir-based therapies achieved satisfactory virological response in Chinese individuals with genotypes 3 and 6 infections: a real-world experience","volume":"14","author":"Tang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jve.2024.100571_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3908767","article-title":"Sofosbuvir-based therapies for patients with hepatitis C virus infection: real-world experience in China","volume":"2018","author":"Hu","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jve.2024.100571_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/14656566.2018.1446945","article-title":"Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations","volume":"19","author":"Wilder","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.jve.2024.100571_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.379","article-title":"Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: analysis of a single-center Department of Veterans Affairs cohort","volume":"6","author":"Benhammou","year":"2018","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.jve.2024.100571_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12985-017-0710-z","article-title":"Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution","volume":"14","author":"Zhang","year":"2017","journal-title":"Virol J"},{"issue":"27","key":"10.1016\/j.jve.2024.100571_bib20","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jve.2024.100571_bib21","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jve.2024.100571_bib22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMc1601160","article-title":"Sofosbuvir and velpatasvir for patients with HCV infection","volume":"374","author":"Assy","year":"2016","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jve.2024.100571_bib23","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jve.2024.100571_bib24","doi-asserted-by":"crossref","first-page":"100557","DOI":"10.1016\/j.jhepr.2022.100557","article-title":"The ALBI score: from liver function in patients with HCC to a general measure of liver function","volume":"4","author":"Toyoda","year":"2022","journal-title":"JHEP Rep."},{"issue":"9","key":"10.1016\/j.jve.2024.100571_bib25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/COC.0000000000000384","article-title":"Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization","volume":"41","author":"Gui","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jve.2024.100571_bib26","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3390\/diagnostics11122236","article-title":"Assessing liver fibrosis using the FIB4 index in the community setting","volume":"11","author":"Blanco-Grau","year":"2021","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.jve.2024.100571_bib27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","article-title":"AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis","volume":"7","author":"Loaeza-del-Castillo","year":"2008","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.jve.2024.100571_bib28","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.14266","article-title":"Adherence to pan-genotypic glecaprevir\/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials","volume":"40","author":"Brown","year":"2020","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.jve.2024.100571_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067259","article-title":"The use of pill counts as a facilitator of adherence with antiretroviral therapy in resource limited settings","volume":"8","author":"Achieng","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jve.2024.100571_bib30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","article-title":"Sofosbuvir\/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan","volume":"11","author":"Cheng","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.jve.2024.100571_bib31","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jve.2024.100571_bib32","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1002\/jmv.27157","article-title":"Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: a nationwide multicenter study by the Japanese Red Cross Liver Study Group","volume":"93","author":"Tada","year":"2021","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.jve.2024.100571_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","article-title":"Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial","volume":"54","author":"Takehara","year":"2019","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jve.2024.100571_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/23744235.2018.1535186","article-title":"Sofosbuvir\/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden","volume":"51","author":"Isakov","year":"2019","journal-title":"Infect Dis (Lond)"},{"issue":"4","key":"10.1016\/j.jve.2024.100571_bib35","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterol"},{"issue":"1","key":"10.1016\/j.jve.2024.100571_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/hepr.13837","article-title":"A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir\/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis","volume":"53","author":"Sano","year":"2023","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.jve.2024.100571_bib37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3350\/cmh.2021.0155","article-title":"Sofosbuvir\/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Mol Hepatol"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664024000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664024000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:09:30Z","timestamp":1737821370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664024000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2055664024000335"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2024.100571","relation":{},"ISSN":["2055-6640"],"issn-type":[{"value":"2055-6640","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life study on the effectiveness and safety of sofosbuvir\/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2024.100571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100571"}}